|
1
|
Byers LA and Rudin CM: Small cell lung
cancer: Where do we go from here? Cancer. 121:664–672. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Merrill RM, Henson DE and Barnes M:
Conditional survival among patients with carcinoma of the lung.
Chest. 116:697–703. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gustafsson BI, Kidd M, Chan A,
Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine
tumors. Cancer. 113:5–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Snow GE, Kasper AC, Busch AM, Schwarz E,
Ewings KE, Bee T, Spinella MJ, Dmitrovsky E and Freemantle SJ: Wnt
pathway reprogramming during human embryonal carcinoma
differentiation and potential for therapeutic targeting. BMC
Cancer. 9:3832009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
You L, He B, Xu Z, Uematsu K, Mazieres J,
Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F and
Jablons DM: Inhibition of Wnt-2-mediated signaling induces
programmed cell death in non-small-cell lung cancer cells.
Oncogene. 23:6170–6174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pacheco-Pinedo EC, Durham AC, Stewart KM,
Goss AM, Lu MM, Demayo FJ and Morrisey EE: Wnt/β-catenin signaling
accelerates mouse lung tumorigenesis by imposing an embryonic
distal progenitor phenotype on lung epithelium. J Clin Invest.
121:1935–1945. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nguyen DX, Chiang AC, Zhang XH, Kim JY,
Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF signaling
through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Howe LR and Brown AM: Wnt signaling and
breast cancer. Cancer Biol Ther. 3:36–41. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khramtsov AI, Khramtsova GF, Tretiakova M,
Huo D, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation
is enriched in basal-like breast cancers and predicts poor outcome.
Am J Pathol. 176:2911–2920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Polakis P: Wnt signaling in cancer. Cold
Spring Harb Perspect Biol. 4:a0080522012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Busch AM, Johnson KC, Stan RV, Sanglikar
A, Ahmed Y, Dmitrovsky E and Freemantle SJ: Evidence for tankyrases
as antineoplastic targets in lung cancer. BMC Cancer. 13:2112013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang SM, Mishina YM, Liu S, Cheung A,
Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner
S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt
signalling. Nature. 461:614–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan
CW, Wei S, Hao W, Kilgore J, Williams NS, et al: Small
molecule-mediated disruption of Wnt-dependent signaling in tissue
regeneration and cancer. Nat Chem Biol. 5:100–107. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
MacNamara B, Wang W, Chen Z, Hou M, Mazur
J, Gruber A and Porwit-MacDonald A: Telomerase activity in relation
to pro- and anti-apoptotic protein expression in high grade
non-Hodgkin's lymphomas. Haematologica. 86:386–393. 2001.PubMed/NCBI
|
|
16
|
Klapper W, Krams M, Qian W, Janssen D and
Parwaresch R: Telomerase activity in B-cell non-Hodgkin lymphomas
is regulated by hTERT transcription and correlated with
telomere-binding protein expression but uncoupled from
proliferation. Br J Cancer. 89:713–719. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gelmini S, Poggesi M, Distante V, Bianchi
S, Simi L, Luconi M, Raggi CC, Cataliotti L, Pazzagli M and Orlando
C: Tankyrase, a positive regulator of telomere elongation, is over
expressed in human breast cancer. Cancer Lett. 216:81–87. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gelmini S, Poggesi M, Pinzani P, Mannurita
SC, Cianchi F, Valanzano R and Orlando C: Distribution of
Tankyrase-1 mRNA expression in colon cancer and its prospective
correlation with progression stage. Oncol Rep. 16:1261–1266.
2006.PubMed/NCBI
|
|
19
|
Gelmini S, Quattrone S, Malentacchi F,
Villari D, Travaglini F, Giannarini G, Della Melina A, Pazzagli M,
Nicita G, Selli C and Orlando C: Tankyrase-1 mRNA expression in
bladder cancer and paired urine sediment: Preliminary experience.
Clin Chem Lab Med. 45:862–866. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shervington A, Patel R, Lu C, Cruickshanks
N, Lea R, Roberts G, Dawson T and Shervington L: Telomerase
subunits expression variation between biopsy samples and cell lines
derived from malignant glioma. Brain Res. 1134:45–52. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tian X, Hou W, Bai S, Fan J, Tong H and Xu
H: XAV939 inhibits the stemness and migration of neuroblastoma
cancer stem cells via repression of tankyrase 1. Int J Oncol.
45:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waaler J, Machon O, Tumova L, Dinh H,
Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova
O, et al: A novel tankyrase inhibitor decreases canonical Wnt
signaling in colon carcinoma cells and reduces tumor growth in
conditional APC mutant mice. Cancer Res. 72:2822–2832. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bilir B, Kucuk O and Moreno CS: Wnt
signaling blockage inhibits cell proliferation and migration, and
induces apoptosis in triple-negative breast cancer cells. J Transl
Med. 11:2802013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jahromi Zare M, Ranjbarian P and Shiravi
S: Cytotoxicity evaluation of Iranian propolis and calcium
hydroxide on dental pulp fibroblasts. J Dent Res Dent Clin Dent
Prospects. 8:130–133. 2014.PubMed/NCBI
|
|
25
|
Fong JT, Jacobs RJ, Moravec DN, Uppada SB,
Botting GM, Nlend M and Puri N: Alternative signaling pathways as
potential therapeutic targets for overcoming EGFR and c-Met
inhibitor resistance in non-small cell lung cancer. PLoS One.
8:e783982013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moon RT: Wnt/β-catenin pathway. Science's
STKE. 2005:cm12005.
|
|
27
|
Klaus A and Birchmeier W: Wnt signalling
and its impact on development and cancer. Nat Rev Cancer.
8:387–398. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salim H, Zong D, Hååg P, Novak M, Mörk B,
Lewensohn R, Lundholm L and Viktorsson K: DKK1 is a potential novel
mediator of cisplatin-refractoriness in non-small cell lung cancer
cell lines. BMC Cancer. 15:6282015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi Y, He B, You L and Jablons DM: Roles
of secreted frizzled-related proteins in cancer. Acta Pharmacol
Sin. 28:1499–1504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shao W and Wang W: Experimental and basic
research affect telomerase inhibitor XAV939 joint nedaplatin on
HeLa cell proliferation and apoptosis. Maternal and Child Health
Care of China. 19:1001–4411. 2014.
|
|
31
|
Partanen JI, Nieminen AI, Mäkelä TP and
Klefstrom J: Suppression of oncogenic properties of c-Myc by
LKB1-controlled epithelial organization. Proc Natl Acad Sci USA.
104:pp. 14694–14699. 2007, View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Guessous F, Johnson EB, Eberhart CG,
Li XN, Shu Q, Fan S, Lal B, Laterra J, Schiff D, et al: Functional
and molecular interactions between the HGF/c-Met pathway and c-Myc
in large-cell medulloblastoma. Lab Invest. 88:98–111. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jirawatnotai S, Hu Y, Livingston DM and
Sicinski P: Proteomic identification of a direct role for cyclin d1
in DNA damage repair. Cancer Res. 72:4289–4293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang Y, Mallampati S, Sun B, Zhang J, Kim
SB, Lee JS, Gong Y, Cai Z and Sun X: Wnt pathway contributes to the
protection by bone marrow stromal cells of acute lymphoblastic
leukemia cells and is a potential therapeutic target. Cancer Lett.
333:9–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dihlmann S and von Knebel Doeberitz M:
Wnt/beta-catenin-pathway as a molecular target for future
anti-cancer therapeutics. Int J Cancer. 113:515–524. 2005.
View Article : Google Scholar : PubMed/NCBI
|
